HC Wainwright Has Pessimistic Outlook of HRMY Q4 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright reduced their Q4 2026 EPS estimates for Harmony Biosciences in a research note issued on Monday, July 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.89 per share for the quarter, down from their previous forecast of $1.03. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.30 per share.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, June 23rd. Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft increased their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Tuesday, June 30th. Finally, Truist Financial raised their target price on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Harmony Biosciences Price Performance

Harmony Biosciences stock opened at $34.86 on Tuesday. The company’s 50 day moving average price is $33.74 and its two-hundred day moving average price is $32.62. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. Harmony Biosciences has a 52 week low of $25.52 and a 52 week high of $40.87. The stock has a market cap of $2.02 billion, a P/E ratio of 14.06, a P/E/G ratio of 0.34 and a beta of 0.94.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The firm had revenue of $215.39 million during the quarter, compared to the consensus estimate of $220.84 million. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 earnings per share.

Hedge Funds Weigh In On Harmony Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the last quarter. Leonteq Securities AG bought a new stake in Harmony Biosciences in the fourth quarter worth $30,000. Allworth Financial LP boosted its position in Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after buying an additional 602 shares during the period. Clearstead Advisors LLC boosted its position in Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after buying an additional 699 shares during the period. Finally, Kestra Advisory Services LLC bought a new position in shares of Harmony Biosciences during the fourth quarter valued at about $47,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.